Skip to main contentAI and Advanced
/
LALPATHLAB · NSEBSE SENSEX74,314.59-0.03%BSE |
NIFTY 5023,270.6+0.23%NSE |
NIFTY BANK56,055.75-0.42%NSE |
NIFTY IT29,155.6+0.23%NSE |
NIFTY AUTO27,159.15+0.99%NSE |
NIFTY FMCG45,572.7+0.03%NSE |
NIFTY PHARMA26,579.25+1.66%NSE |
NIFTY 50022,654.65+0.54%NSE |
LA
NSE · Equity shares · Healthcare Facilities38.30 · 2.02%
Dr. Lal PathLabs LALPATHLAB
NSE:INR 1,934
BSE:INR 1,934
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceLast market snapshot
Company fundamentalsStale · last-known data
Research sections9 of 9 availableMissing source values remain unavailable, never zero-filled.
AI analysis and Advanced tools for LALPATHLAB
Analysis, reports, chat and Advanced access use the same Rusaka Markets account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 1,895.7
Day rangeINR 1,870 — INR 2,038.6
52-week rangeINR 1,272 — INR 2,038.6
Volume15.61 L
Market cap32,296.76
P/E21
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)2,762.91
Net Income (INR Cr)504.78
Rev Growth (5 Year %)11.81
EPS Growth (5 Year %)11.37
P/E Ratio21
EPS31.61
Research path: Interpret Dr. Lal PathLabs's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
LALPATHLABDr. Lal PathLabs1d · INR · NSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 3,146 | 2,716.79 | 2,455.96 |
| Accumulated Depreciation Total | -612.6 | -522.06 | -447.94 |
| Cash Equivalents | 217.95 | 268.59 | 336.06 |
| Other Liabilities Total | 2.65 | 1.95 | 1.61 |
| Accrued Expenses | 32.89 | Not available | Not available |
| Common Stock Total | 167.56 | 83.59 | 83.48 |
| Other Equity Total | -0.28 | -0.55 | -0.61 |
| Other Current Assets Total | 1.37 | 17.09 | 17.05 |
| Prepaid Expenses | 18.17 | 16.3 | 16.42 |
| Total Assets | 3,146 | 2,716.79 | 2,455.96 |
| Current Portof LT Debt/Capital Leases | 53.57 | 54.79 | 143.91 |
| Additional Paid-In Capital | 82.81 | 124.79 | 104.89 |
| Cash | 24.85 | 24.03 | 24.88 |
| Total Equity | 2,508.14 | 2,172.72 | 1,849.28 |
| Long Term Investments | 32.78 | 33.36 | 33.71 |
| Retained Earnings(Accumulated Deficit) | 2,300.08 | 1,984.37 | 1,675.91 |
| Treasury Stock-Common | -42.04 | -19.48 | -14.39 |
| Total Common Shares Outstanding | 16.7 | 16.67 | 16.64 |
| Property/Plant/Equipment Total-Gross | 1,101.92 | 861.34 | 794.92 |
| Tangible Book Valueper Share Common Eq | 105.84 | 82.38 | 59.89 |
| Goodwill Net | 548.19 | 548.11 | 548.19 |
| Total Liabilities | 637.86 | 544.07 | 606.68 |
| Total Debt | 198.99 | 157.43 | 246.93 |
| Short Term Investments | 1,143.71 | 871.45 | 581.66 |
| Cashand Short Term Investments | 1,386.5 | 1,164.07 | 942.6 |
| Total Receivables Net | 113.71 | 125.85 | 111.88 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 |
| Deferred Income Tax | 6.03 | 3.37 | 2.39 |
| Accounts Receivable-Trade Net | 110.69 | 122.7 | 108.88 |
| Property/Plant/Equipment Total-Net | 489.32 | 339.28 | 346.98 |
| Minority Interest | 33.14 | 33.76 | 36.08 |
| Total Current Liabilities | 450.62 | 402.35 | 463.58 |
| Total Inventory | 46.73 | 40.19 | 38.76 |
| Accounts Payable | 180.6 | 198.85 | 186.57 |
| Other Currentliabilities Total | 183.55 | 148.71 | 133.1 |
| Total Long Term Debt | 145.42 | 102.64 | 103.02 |
| Intangibles Net | 192.6 | 251.07 | 304.31 |
| Other Long Term Assets Total | 296.97 | 168.3 | 77.2 |
| Note Receivable-Long Term | 19.65 | 13.16 | 18.89 |
| Total Current Assets | 1,566.49 | 1,363.51 | 1,126.7 |
| Capital Lease Obligations | 145.42 | 102.64 | 103.02 |
| Long Term Debt | Not available | 0 | Not available |
Fundamentals
Valuation and ratios
Valuation
PEG Ratio2.07
Price to Sale Ratio11.69
Growth
Debt 5Yr CAGR %5.75
Margins
Operating Margin 12m22
Operating Margin 5y Avg20.92
Net Profit Margin 12m18.9
Net Profit Margin 5y16.92
Yield
Dividend Yield %0.85
Risk and consensus
Source-qualified signals
Risk metrics
Overall RiskBalanced risk
Board Risk32.18
Analyst consensus
ConsensusBuy
Consensus score2.00
Analyst opinions25
Strong Sell count0
Sell count3
Hold count3
Buy count10
Strong Buy count9
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Apollo Hospitals Enterprise | INR 8,812.9 | 1.27 L | 64.93 | — |
| Max Healthcare Institute | INR 1,075 | 1.05 L | 71.47 | — |
| Fortis Healthcare | INR 935 | 70,588.59 | 67.89 | — |
| Aster DM Healthcare | INR 844.4 | 44,157.18 | 102.55 | — |
| Narayana Hrudayalaya | INR 1,881 | 38,187.34 | 48.07 | — |
Shareholding
Ownership
- Promoter
- 53.19%
- FII
- 17.35%
- MF
- 18.79%
- Other
- 10.67%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Dr Lal Pathlabs Ltd is Rated Hold by MarketsMOJO - Markets MojoMarket news · 3 Jun 2026, 7:20 pm
Dr Lal Pathlabs Ltd is Rated Hold by MarketsMOJO Markets Mojo
Dr Lal Pathlabs Ltd Technical Momentum Shifts Amid Mixed Indicator Signals - Markets MojoMarket news · 3 Jun 2026, 8:05 am
Dr Lal Pathlabs Ltd Technical Momentum Shifts Amid Mixed Indicator Signals Markets Mojo
Dr Lal Pathlabs Ltd Technical Momentum Shifts Amid Mixed Market Signals - Markets MojoMarket news · 2 Jun 2026, 9:12 am
Dr Lal Pathlabs Ltd Technical Momentum Shifts Amid Mixed Market Signals Markets Mojo
Dr. Lal PathLabs Schedules Analyst and Institutional Investor Meeting on May 20, 2026 - scanx.tradeMarket news · 20 May 2026, 12:30 pm
Dr. Lal PathLabs Schedules Analyst and Institutional Investor Meeting on May 20, 2026 scanx.trade
Dr. Lal PathLabs FY26 Audited Results: Revenue Up 12.2%, Dubai Subsidiary Approved - scanx.tradeMarket news · 7 May 2026, 12:30 pm
Dr. Lal PathLabs FY26 Audited Results: Revenue Up 12.2%, Dubai Subsidiary Approved scanx.trade
Dr Lal PathLab Standalone March 2026 Net Sales at Rs 675.20 crore, up 16.98% Y-o-Y - Moneycontrol.comMarket news · 5 May 2026, 12:30 pm
Dr Lal PathLab Standalone March 2026 Net Sales at Rs 675.20 crore, up 16.98% Y-o-Y Moneycontrol.com
Corporate actions
Events
- dividendRs.5.0000 per share(50%)Interim Dividend
- annual General MeetingAGM
- board MeetingsQuarterly Results
- dividendRs.4.0000 per share(40%)Final Dividend
- board MeetingsAudited Results & Final Dividend
- dividendRs.3.5000 per share(35%)Third Interim Dividend
- board MeetingsTo consider other business matters.
- bonusBonus issue of equity shares in the ratio of 1:1 of Rs. 10/-.
Rusaka Markets Community
Discussion and sentiment for Dr. Lal PathLabs
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and Rusaka Markets AI.
Checking your Rusaka Markets account…
Company profile
Business information
What the company does
Dr. Lal PathLabs Limited is an India-based provider of diagnostic and related healthcare tests and services. The Company is engaged primarily in the business of running laboratories for carrying out pathological investigations in various branches of bio-chemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigations. It offers a range of tests, including Pregnancy Test, Full Body Checkups, Covid 19 Test, Heart Test, Kidney Test, Liver Test, Cholesterol Test, Hepatitis B Test, Kidney Function Test, Sugar Test, Thyroid Test, Typhoid Test, Uric Acid Test, Vitamin B12 Test and vitamin D Test. It has approximately 298 clinical laboratories (including National Reference Lab at Delhi, Regional Reference Lab in Kolkata, Bangalore and Mumbai), 6,607 patient service centers, and 12,365 pick-up points (PUPs). Its customers include individual patients, hospitals, and corporate customers.
Company facts
- Industry
- Healthcare Facilities
- Sector
- Healthcare Facilities
- NSE Code
- LALPATHLAB
- BSE Code
- 539524
Questions
Stock FAQ
What is the symbol and ISIN of Dr. Lal PathLabs?
Dr. Lal PathLabs has the symbol LALPATHLAB and ISIN - INE600L01024.
What is the current price of Dr. Lal PathLabs?
Dr. Lal PathLabs is currently trading at INR 1,934.00.
What are the year high and year low of Dr. Lal PathLabs?
Dr. Lal PathLabs has a year high of INR 2,038.60 and a year low of INR 1,272.00.
What is the market capitalization of Dr. Lal PathLabs?
Dr. Lal PathLabs has a market capitalization of INR 32,296.76 crore.
What is the P/E ratio of Dr. Lal PathLabs?
Dr. Lal PathLabs has a P/E ratio of 21.00.
What is the dividend yield of Dr. Lal PathLabs?
Dr. Lal PathLabs has a dividend yield of 0.85%.
How is the financial performance of Dr. Lal PathLabs based on revenue, net income, and EPS?
Dr. Lal PathLabs has revenue of INR 2,762.91 crore, net income of INR 504.78 crore, and EPS of INR 33.72.
What is the book value of Dr. Lal PathLabs?
Dr. Lal PathLabs has a book value of NA.
What is the debt-to-equity ratio of Dr. Lal PathLabs?
Dr. Lal PathLabs has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Dr. Lal PathLabs?
Dr. Lal PathLabs has a price-to-book ratio of NA and a price-to-sales ratio of 11.69.
Corporate-action adjustment is provider-defined. Rusaka Markets research and computed indicators are not investment advice.